To support the measures to contain the coronavirus, our office is currently only staffed to a limited extent. Visits are not possible at the moment. However, our employees can be reached by phone and e-mail during office hours.
Technology Transfer for the Max Planck Society
Max Planck Innovation is responsible for technology transfer from the research institutes of the Max Planck Society.
The Max Planck Society (MPG) operates as Germany’s most successful organization in basic research and is worldrenowned for its cutting-edge research. In many cases this cutting-edge research also forms the basis for innovative products and services that are implemented through licensing and spin-off companies.
Thus we perform an important task: the transfer of basic research results into products, which contribute to the economic and social progress.
50 years of Max Planck innovation - 50 years of technology transfer for the Max Planck Society
We are your contact for
We advise and support scientists in the evaluation and patenting of research results while helping to establish the best success in the market.
Do you have a business idea? If so, talk to us! We offer founders a comprehensive range of services from evaluating a spin-off project through to fundraising support.
We provide future-oriented companies with access to the patented inventions and know-how of the Max Planck Institutes and offer them licensing opportunities.
Multifunctional RFID-based Platform for Animal Observation and Manipulation
Bioinspired Liquid-Superrepellent Fibrillar Dry Adhesives
Novel method for analysis of complex carbohydrate structures by ion-mobility mass spectrometry (IM-MS)
Novel protein expression optimization method combining machine learning with insights from mechanistic modelling of mRNA translation
High-precision base editors for site-specific single nucleotide conversion
First in class “semi-live” RNA vaccines against SARS-CoV-2, RSV and other respiratory viruses
A novel type of influenza A virus-derived Defective interfering Particle for antiviral therapy
Nanographene-based dyes as high performance probes for super-resolution microscopy
Cellink acquires MPG spin-off Scienion AG for 80 million euros
Development of novel proteasome inhibitors for treating cancer, inflammatory and autoimmune disorders
Drug candidate for cancer immunotherapy enters Phase I study
Scientists are developing a procedure whereby vaccines can be absorbed through the skin
New treatment method for curing HIV being tested in clinical study
Patents, spin-off companies and license agreements
Quench Bio closes $ 50M series A financing to advance first-in-class medicines against severe inflammatory diseases
A therapy with VPM1002 is effective for bladder cancer patients
Newsletter Sign up
Sign up for our newsletter and our press releases and receive the latest information on technology transfer from the Max Planck Society: Sign up